Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâ€™s device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

10-22 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-28	SEK 1.260	+4.13%	36,347
26-09-25	SEK 1.210	-0.82%	43,372
26-09-24	SEK 1.220	-2.01%	37,014
26-09-23	SEK 1.245	+2.47%	31,714
26-09-22	SEK 1.215	-1.62%	5,497

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 12:00:00 2026-09-28 EDT			5-day change	1st Jan Change
1.260 ^SEK	+4.13%		+2.02%	+10.53%

08-20	Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI

Market Cap	121M 12.17M 10.7M 10.12M 9.18M 17.24M 1.17B 17.34M 46.8M 596M 45.69M 44.7M 1.92B	P/E 2026 *	-14x	P/E 2027 *	-3.32x
Enterprise Value	84.18M 8.45M 7.43M 7.03M 6.38M 11.98M 811M 12.05M 32.51M 414M 31.74M 31.05M 1.33B	EV / Sales 2026 *	2.9x	EV / Sales 2027 *	-
Free-Float	41.18%	Yield 2026 *	-	Yield 2027 *	-

08-20	Iconovo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI
06-22	Iconovo, Lonza Finalize Long-term Strategic Collaboration	MT
04-24	Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Iconovo Q1 net sales up at 0.7 mln SEK	RE
04-14	Iconovo appoints Anders Mañsson as CEO	RE
04-14	Iconovo AB Appoints Anders Månsson as Permanent CEO, Effective April 14, 2026	CI
03-17	Iconovo says no TO 1 was used for subscription	RE
03-02	Iconovo announces final outcome of rights issue	RE
02-25	Iconovo and Lonza sign LOI regarding strategic collaboration	RE
02-24	Iconovo AB (Publ.) and Lonza Signs LOI Regarding Strategic Collaboration	CI
02-12	Iconovo Q4 net sales SEK 504,000	RE
02-12	Iconovo AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

08-24	Iconovo: Still waiting for commercial proof – Q2 review	AQ
07-03	Iconovo AB (publ) reintroduces liquidity provider agreement with Pareto Securities AB	AQ
06-29	Iconovo terminates liquidity provider agreement	AQ
06-22	Iconovo and Lonza sign Strategic Collaboration Agreement	AQ
04-24	Iconovo: Limited progress – Q1 review	AQ

Iconovo AB Stock

Stocks

ICO

SE0010868943

Medical Equipment, Supplies & Distribution

Valuation: Iconovo AB

Chart: Iconovo AB

Latest news: Iconovo AB

Analysts' recommendations: Iconovo AB

Press Releases: Iconovo AB

Quotes and Performance

Price Extremes

Managers and Directors: Iconovo AB

Latest insider transactions

Medical Supplies

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 day	+4.13%
1 week	+2.02%
1 month	+1.61%
3 months	+12.50%
6 months	+6.33%
Current year	+10.53%

1 week	1.18	1.3
1 month	1.14	1.5
Current year	0.87	1.5
1 year	0.87	2.4
3 years	0.87	16.95
5 years	0.87	90
10 years	0.87	99.8

Manager	Title	Age	Since
Anders Månsson CEO	Chief Executive Officer	59	2025-10-30
Henrik Simonsen DFI	Director of Finance/CFO	63	2023-03-31
Mikael Arinder COO	Chief Operating Officer	62	2015-12-31

Director	Title	Age	Since
Mats Håkan Johansson CHM	Chairman	65	2012-12-31
Orest Lastow BRD	Director/Board Member	62	2012-12-31
Berndt David Lennart Axelsson BRD	Director/Board Member	67	2012-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/22/22	Mats Håkan Johansson	Buy	Founder	500	0.0057%
9/21/22	Johan Wäborg	Buy	Chief Executive Officer	1,000	0.0113%
9/16/22	Agneta Walhagen	Buy	Director	840	0.0095%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ICONOVO AB	+4.13%	+2.02%	-43.24%	-90.63%	11.73M
COLOPLAST A/S	+0.77%	+0.07%	-23.57%	-43.29%	14.34B
INTCO MEDICAL TECHNOLOGY CO., LTD.	-1.51%	-6.20%	+28.18%	+116.55%	4.74B
ZHENDE MEDICAL CO., LTD.	-4.68%	-6.84%	+74.67%	+175.95%	3.09B
WINNER MEDICAL CO., LTD.	-0.78%	-1.25%	-22.34%	-28.79%	2.52B
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-0.15%	-0.61%	-43.08%	-52.76%	1.85B
JAFRON BIOMEDICAL CO.,LTD.	+0.27%	-1.12%	-31.85%	-33.36%	1.73B
TOP GLOVE CORPORATION BHD.	0.00%	-5.23%	+25.00%	-6.45%	1.49B
ANHUI HONGYU WUZHOU MEDICAL MANUFACTURER CO.,LTD.	+4.41%	+9.93%	+204.64%	+248.14%	1.24B
CAINA TECHNOLOGY CO., LTD.	+1.84%	+21.45%	+164.55%	+64.70%	1.16B
Average	+0.36%	+1.64%	+33.30%	+35.01%	3.22B
Weighted average by Cap.	-0.18%	-0.71%	+9.83%	+19.27%

	2026 *	2027 *
Net sales	29M 2.91M 2.56M 2.42M 2.2M 4.13M 280M 4.15M 11.2M 143M 10.93M 10.7M 458M	-
Net income	-6M -603K -530K -501K -455K -854K -57.84M -859K -2.32M -29.51M -2.26M -2.21M -94.84M	-37M -3.72M -3.27M -3.09M -2.8M -5.26M -357M -5.29M -14.29M -182M -13.95M -13.65M -585M
Net Debt	-37M -3.72M -3.27M -3.09M -2.8M -5.26M -357M -5.29M -14.29M -182M -13.95M -13.65M -585M	-44M -4.42M -3.89M -3.67M -3.33M -6.26M -424M -6.3M -16.99M -216M -16.59M -16.23M -696M